Mainz Biomed Provides Half Year 2024 Corporate Update

Mainz Biomed N.V. (NASDAQ: MYNZ), a company specializing in the early detection of cancer, announced its major accomplishments for the first half of 2024. The company's financial results are expected in September 2024.

Key achievements include the presentation of industry-leading results of its pooled study at ASCO 2024, demonstrating significant sensitivity for colorectal cancer (CRC) and advanced adenomas. This marks the third confirmation of Mainz Biomed’s mRNA biomarkers' performance.

Mainz Biomed received a Poster of Distinction at Digestive Disease Week, showcasing high sensitivity rates for colorectal cancer and advanced precancerous lesions. The company also engaged in key congresses in Germany, emphasizing the importance of gut health in disease manifestation.

The company is making strategic moves to gain FDA premarket approval and advance their market strategy in the U.S. They have partnered with Trusted Health Advisors and TomaLab to support their diagnostic solutions in the U.S. and Italy, respectively.

CEO Guido Baechler expressed satisfaction with the progress made and looks forward to the next steps, including the FDA pivotal CRC study.